Follow the Pundits
Tag: John Paulson
📱 Thryv (THRY): Why John Paulson Just Bet Another $7.2 Million on This AI Turnaround
Thryv was once known for Yellow Pages directories. Today, roughly 76% of its revenue comes from SaaS, management is expanding its AI platform, and legendary investor John Paulson continues buying shares. We examine whether Wall Street is still valuing yesterday's business while tomorrow's company quietly takes shape.
🏔️ John Paulson 2025: From "Short of the Century" to the "Long of the Decade"
John Paulson is back. After years under the radar, the legendary investor posted a 58% return in 2025—driven by high-conviction bets in biotech, gold, and strategic minerals. This is not diversification. This is precision investing.
John Paulson’s $5,000 Gold Bet: Genius or Gamble? 🚀
A hyper-concentrated portfolio, a $5,000 gold target, and massive biotech bets—John Paulson is back with one of the boldest strategies in markets today.
Paulson & Co Keeps Adding to His Bausch Health Stake: Should Investors See Eye to Eye With Him?
Billionaire John Paulson now owns nearly 19% of Bausch Health — and he keeps buying. With improving earnings, low valuation, and high risk, BHC may be a speculative value play worth watching.
John Paulson Is Loading Up on Perpetua Resources. Should You?
John Paulson knows a good discount when he sees one—and he just grabbed another $100M worth of Perpetua Resources (PPTA). But what is this gold-and-antimony play really about? From Idaho mines to strategic minerals and a wink at squirrel invasions, we break it all down.
Bausch Health: Paulson Doubles Down, Stock Breaks Out, Recovery Accelerates
Bausch Health ($BHC) is back in the spotlight as legendary investor John Paulson adds millions more in shares, fueling a breakout rally. With Q2 earnings showing revenue growth, profit rebound, and debt repayment plans, could BHC be staging its long-awaited comeback?